Jack Anders Sells 10,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total value of $400,300.00. Following the completion of the transaction, the chief financial officer now directly owns 101,959 shares of the company’s stock, valued at $4,081,418.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jack Anders also recently made the following trade(s):

• On Monday, March 18th, Jack Anders sold 1,261 shares of Revolution Medicines stock. The stock was sold at an average price of $31.58, for a total value of $39,822.38.

Revolution Medicines Price Performance

Shares of RVMD opened at $40.20 on Friday. Revolution Medicines, Inc. has a 52-week low of $15.44 and a 52-week high of $40.21. The stock’s 50-day simple moving average is $33.04 and its 200 day simple moving average is $28.30.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Monday, February 26th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.29). The firm had revenue of $0.74 million for the quarter, compared to the consensus estimate of $1.20 million. The company’s revenue for the quarter was down 95.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.63) EPS. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Manchester Capital Management LLC bought a new stake in shares of Revolution Medicines during the 4th quarter valued at about $80,000. China Universal Asset Management Co. Ltd. lifted its position in Revolution Medicines by 101.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,802 shares of the company’s stock valued at $78,000 after purchasing an additional 1,409 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Revolution Medicines in the 1st quarter worth approximately $104,000. Fred Alger Management LLC purchased a new position in Revolution Medicines in the 3rd quarter worth approximately $126,000. Finally, Federated Hermes Inc. bought a new position in shares of Revolution Medicines in the 3rd quarter worth $126,000. 94.34% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on RVMD shares. Needham & Company LLC reiterated a “buy” rating and set a $46.00 target price (up from $36.00) on shares of Revolution Medicines in a research note on Monday, April 8th. Oppenheimer boosted their target price on shares of Revolution Medicines from $43.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, April 12th. Raymond James raised shares of Revolution Medicines from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $36.00 to $48.00 in a research report on Wednesday, April 10th. Bank of America raised shares of Revolution Medicines from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $31.00 to $34.00 in a report on Friday, January 5th. Finally, Piper Sandler assumed coverage on Revolution Medicines in a report on Monday, March 11th. They set an “overweight” rating and a $43.00 price objective for the company. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $41.20.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.